bisphosphocin nu-3

Bisphosphocin Nu-3 is a novel synthetic small molecule antimicrobial under investigation for the treatment of chronic diabetic foot ulcers and other infections. It belongs to a new class of antimicrobials called bisphosphocins and has demonstrated broad-spectrum activity against Gram-positive, Gram-negative, and antibiotic-resistant bacteria. The drug is being developed primarily as a topical gel for use in patients with Type I or II diabetes mellitus who have non-healing or infected diabetic foot ulcers. Clinical studies have shown that Bisphosphocin Nu-3 can significantly reduce ulcer area and microbiological load compared to placebo, with no reported treatment-related adverse events. The developer is Lakewood-Amedex, which has advanced the drug through Phase 2 clinical trials[1][2][4][6][7]. Bisphosphocin Nu‑3 represents a first-in-class approach targeting bacterial **cell membrane structures** rather than traditional protein targets.

Brand names

Nu-3Nu3Nu 3

Other names

3'-thymidylic acid, monobutyl ester, 5'-(butyl hydrogen phosphate)UNII-8BK3483OW5UNII8BK3483OW5UNII 8BK3483OW5